CD274 and type 1 diabetes mellitus: Therapeutic exploitation of this pathway for controlling T1D could be achieved via tolerogenic dendritic cells (DCs), microbiota transfer, or grafting of engineered β cells expressing PD-L1; these options have been discussed elsewhere [61].